Supreme Court Rules on Biosimilar Products
Posted Jun 16, 2017
The Supreme Court ruled that makers of copycat versions of biologic drugs, known as “biosimilars” can give 180-day notice of sales before their products win approval by the Food and Drug Administration. The ruling should speed up access to lower-cost drugs to the public, and possibly mean billions of dollars in revenue loss for the makers of the original drug versions. Read articles in Reuters and the Washington Post.